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A series of thiazole based amides have been designed and synthesized by solution-phase amide coupling of  
2-aminothiazole and its derivatives with naturally occurring aromatic and heteroaromatic acids in excellent yield via 
DIC/HOBt protocol All the compounds have been evaluated for their antitubercular activity against M. tuberculosis virulent 
strain M. tuberculosis H37Rv and PknG inhibitory activity in the presence and absence of the inhibitors The compounds 
display moderate to significant PknG inhibitory activity (9.1-15.6% inhibition at 100 µM) as compared to the standard 
inhibitors and very moderate in vitro antitubercular activities against M. tuberculosis virulent strain M. tuberculosis H37Rv. 
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Tuberculosis is an infectious disease, which is caused 
by the bacteria Mycobacterium tuberculosis  
(M. tuberculosis). It is one of the most important global 
health problems. According to WHO, 1.5 million 
people died from tuberculosis out of 10 million new 
reported cases. The virulence of pathogenic 
mycobacteria is due to its capacity to survive for a 
prolonged period within macrophages1-3. It is revealed 
by genomic study that the genome of Mycobacterium 
tuberculosis constitutes of 11 serine/threonine protein 
kinases, out of which protein kinase G (PknG) plays a 
pivotal role in regulatory process within the 
mycobacterial cell and signaling cascade of the 
infected host cell4-6. Although PknG is not required for 
mycobacterial growth, it is crucial for the survival 
within host macrophage by blocking phagosome-
lysosome fusion within infected macrophages4,7. 
Furthermore, PknG has also been reported to be 
necessary for acquiring intrinsic antibiotic resistance in 
bacteria8. Therefore, blocking PknG with the use of the 
specific PknG inhibitor like AX20017, will result in the 
inhibition of internalized mycobacteria. These findings 
make PknG an attractive and promising drug target for 
the treatment of M. tuberculosis. There are reports 
which have identified several small molecules 
(Figure 1), which act as PknG inhibitors, but their 
numbers are very limited9-11. Therefore, it is of utmost 
importance to search for new small molecules that act 
as PknG inhibitors. 
Thiazole and its natural or synthetic derivatives 
displayed a variety of biological as well as 
pharmacological activities like antitubercular, 
analgesic, anti-inflammatory, antibacterial and 
antifungal, central nervous system stimulation, 
algicidal, anti-HIV, antiallergic, antischizophrenic, 
antihypertension, antihypnotics, anti-tumor and for the 
treatment of pain12-24. Furthermore, thiazole 
derivatives were also reported to display anti 
degenerative activity and coupled with other aromatic 
ring systems, can form new biologically active 
compounds25. Nitazoxanide (NTZ) and its hydrolyzed 
active metabolite Tizoxanide (TIZ), which have been 
approved by FDA for the treatment of protozoal 
infection in 2002 have effectively killed both the 
replicating and nonreplicating Mtb with MIC value 16 
µg/mL, revealed the presence of thiazole unit in their 
chemical structure (Figure 2)26,27. Recently Sacchettini 
and their co-workers also reported I and II as 
inhibitors for Mycobacterium tuberculosis ATP 
Phosphoribosyl Transferase (HisG)28. Several 
Distamycin analogs (III) were also reported to have 
antimicrobial activities (Figure 2)29. 
A closer look at the chemical structure of 
compounds shown in Figure 2, showed the presence 
of thiazole unit having an amide group at its 2-
position. Keeping in view of the above discussion, we 
were interested in synthesizing a series of small 
molecules having the 2-amidothiazole unit in their 




chemical structure and to evaluate them for their 
antitubercular and pknG inhibitory activity. 
 
Results and Discussion 
 
Chemistry 
Standard DIC/HOBt protocol for acid and amine 
coupling has been adopted for the synthesis of 
targeted compounds. The synthetic strategy started 
from the reaction between 2-aminothiazole and 
phenylacetic acid by using 1-hydroxy benzotriazole 
(HOBt), diisopropyl carbodiimide (DIC) and  
4-dimethylamino pyridine (DMAP) as coupling 
reagents in anhydrous CH2Cl2 under N2 atmosphere 
for 5 h at 0-5°C to get the desired 2-phenyl-N-(1,3-
thiazol-2-yl)acetamide (1) in 86% yield (Scheme I). 
The structure of compound 1 has been established 
based on their spectroscopic data and microanalysis. 
The IR spectrum of the compound 1 exhibited 
absorption bands at 3309 cm−1 for the NH group and 
at 1675 cm−1 for CO which proves the presence of 
both the groups in compound 1. The ESI-MS 
spectrum (Mass Spectrum) of the compound 1 
showed a peak at m/z 219 [M+H]+ corresponding to its 
molecular formula C11H10N2OS. In 1H NMR 
 
 








Scheme I — Synthesis of prototype compound 1 




spectrum, H-4 and H-5 proton of the thiazole ring was 
observed as two distinct doublets at δ 7.47 and 7.02 
respectively with coupling constant J = 2.3 Hz. 
Whereas all the other five aromatic protons of the 
phenyl ring appeared as a multiplet at δ 7.40-7.28. 
The methylene proton appeared as a singlet at δ 3.89. 
In the 13C NMR spectrum, the carbonyl group 
appeared at δ 169.0. The quaternary carbon of the 
thiazole ring was observed at δ 159.0 while the two 
CH carbon of thiazole ring were observed at δ 136.9 
and 113.0 respectively. Quaternary carbon of the 
phenyl ring was observed at δ 134.2 whereas the other 
five aromatic CH’s of the phenyl ring were observed 
at δ 129.1, 128.4, and 126.9 respectively. The 
methylene carbon signal was observed at δ 42.4. 
After the successful synthesis and spectroscopic 
characterization of the compound 1, we have further 
synthesized a series of compounds 2-11, obtained by 
the coupling with different naturally occurring 
aromatic acids with 2-amino thiazole and its various 
derivatives by adopting the above DIC/HOBt 
coupling protocol (Scheme II, Table I). 
The structures of all the above compounds 2-11 
were also confirmed on the basis of their 
spectroscopic data and microanalyses. In the case of 
1H NMR spectra of compound 9, 10 and 11, the two 
CH protons were observed at around δ 7.76 and 6.94 
with a coupling constant around 10.0 Hz, which 
confirms the trans geometry. In the case of compound 
8, the CH2 group was observed at δ 4.23 with 
coupling constant 3.8 Hz. Furthermore, in 13C NMR, 
compounds 2-11 showed the usual peak as expected. 
The IR spectrum of the compounds 2-11 also 
exhibited absorption bands around 3300 and 1670 
cm−1 which proved the presence of NH and CO group 
respectively. The ESI-MS spectra of the compounds 
2-11 showed their characteristic [M+H]+ peaks. 
 
Biology 
The above-synthesized compounds (1-11) were 
evaluated against M. tuberculosis virulent strain  
M. tuberculosis H37Rv. The MIC (Minimum inhibitory 
concentration) values were determined using the agar 
microdilution method30-32. The results are given  
in Table II. 
As evident from Table II, among all the tested 
compounds only three compounds 5, 8, and 11 were 
found active at the minimum inhibitory concentration 
(MIC) 12.5 µg/mL against M. tuberculosis, while the 
rest of the compounds were inactive at MIC 12.5 
µg/mL. The most plausible explanation may be that 
these compounds are unable to penetrate the cell wall 
of M. tuberculosis. 
All the above compounds 1-11were also screened 
for their mycobacterial serine-threonine protein kinase 
G (PknG) inhibitory activity in the presence and the 
absence of the inhibitors. Among all the above-
screened, compounds 1-11 showed moderate 
inhibition ranging from 9.1-15.6%. AX20017 was 
used as a standard PknG inhibitor which showed 41% 
inhibition of enzyme activity at 100 µm33. The results 
are tabulated below (Table III). 
From Table III, it is clear that compounds 1, 2, 3, 
and 4 inhibit 31, 38, 34, and, 31% relative to standard 
compound AX20017 respectively. It is clear from the 
structure that the compound having the benzothiazolyl 
group at one end and the benzyl group at the other end 
are the most active compounds. Furthermore, the 
compounds obtained from phenylacetic acid are found 
to be more active than the compounds obtained from 
nicotinic acid, cinnamic acid, and hippuric acid. On 
the other hand, it is found that compounds obtained 
from the amines having electron-donating groups  





Materials and Methods 
All chemicals were purchased from commercial 
sources (Sigma Aldrich and Spectrochem) and used 
as such without purification. Progress of the 
reactions was monitored by TLC on E. Merck 
Kieselgel 60 F254, with detection by spraying a 20% 
aq KMnO4 solution and UV light. Column 
chromatography was performed over silica gel (60-
120 mesh E. Merck). IR spectra were recorded with 
KBr (Pressed Pellet Technique) with a 
Perkin−Elmer Spectrum RX-1 (4000-450 cm−1) 
spectrophotometer. 1H and 13C NMR spectra were 
recorded on a Bruker DRX-200 instrument in 
CDCl3+CCl4 or CDCl3+DMSO-d6 solvent. 
Chemical shift values (δ) are reported in ppm 
relative to TMS (tetramethylsilane) as internal 
standard and coupling constants (J) in Hertz. 
Splitting pattern has been described as follows: s 
 
Scheme II — General scheme for the synthesis of compounds 2-11 




(singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet). ESI mass spectra were recorded using 
Quattro II (Micromass). Elemental analyses  




General procedure for the synthesis of compounds 1-11 
To a solution of aromatic acid (1.05 eq) in dry 
dichloromethane (25 mL) at 0-5°C, anhydrous  
1-hydroxybenzotriazole (1.05 eq.) and  
Table I — The reaction of different naturally occurring aromatic acids and heterocyclic amines 





































4-dimethylaminopyridine (1.05 eq.) were added under 
nitrogen atmosphere. The reaction mixture was 
allowed to stir for 10 min. A solution of N,  
N‘-diisopropylcarbodiimide (1.05 eq.) diluted with 
dry dichloromethane (10 mL) was added slowly to the 
reaction mixture. The reaction mixture was allowed to 
stir for 10 min at 0-5°C. A solution of aromatic amine 
in dry dichloromethane (15 mL) was added slowly to 
the above reaction mixture while maintaining the 
temperature of the reaction between 0-5°C under 
nitrogen atmosphere. After the completion of the 
reaction, the reaction mixture was concentrated under 
reduced pressure while maintaining the temperature 
of the water bath not exceeding 40°C. The residue, so 
obtained, was purified by column chromatography 
(SiO2, 60-120 mesh) using appropriate eluent to give 
the desired compounds 1-11 in good yields. 
 
2-Phenyl-N-(1,3-thiazol-2-yl)acetamide, 1 
It was obtained by using 2-aminothiazole (0.25 g, 
2.50 mmol), phenylacetic acid (0.36 g, 2.64 mmol), 
DMAP (0.32 g, 2.62 mmol), HOBt (0.35 g, 2.59 
mmol), DIC (0.4 mL, 2.55 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 1 as a white solid powder (0.47 g. Yield 
86%). Rf 0.5 (50% hexane:ethylacetate). m.p.153-154°C. 
IR (KBr): 3414, 3309, 2937, 2370, 1675, 1580, 1344, 
1275, 1063, 716 cm−1; 1H NMR (200 MHz, 
CDCl3+CCl4): δ 7.47 (d, J = 2.34 Hz, 1H, CH, ArH ), 
7.40-7.30 (m, 5H, CH, ArH), 7.02 (d, J = 2.36 Hz, 
1H, CH, ArH), 3.89 (s, 2H, CH2); 13C NMR (50 MHz, 
CDCl3+CCl4): δ 169.0 (CO), 159.0 (ArC), 136.9 
(ArCH), 134.2 (ArC), 129.1 (2ArCH), 128.4(2ArCH), 
126.9 (ArCH), 113.0 (ArCH), 42.4 (CH2); MS (ESI+): 
m/z 219 [M+H]+. Anal. Calcd for C11H10N2OS: C, 




It was obtained by using 2-aminobenzothiazole 
(0.25 g, 1.66 mmol), phenylacetic acid (0.24 g, 1.76 
mmol), DMAP (0.21 g, 1.71 mmol), HOBt (0.24 g, 
1.78 mmol), DIC (0.3 mL, 1.91 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 2 as a white solid powder (0.38 g. Yield 
85%). Rf 0.5 (50% hexane:ethylacetate). m.p.159-160°C. 
IR (KBr): 3485, 3201, 2973, 2366, 1695, 1579, 1272, 
1054, 716 cm−1; 1H NMR (300 MHz, CDCl3+DMSO-
d6): δ 7.86 (d, J = 4.96 Hz, 1H, ArH), 7.77 (d, J = 5.30 
Hz, 1H, ArH), 7.47-7.42 (m, 1H, ArH), 7.42-7.28 (m, 
4H, ArH), 7.22-7.20 (m, 2H, ArH), 3.85 (s, 2H, CH2); 
13C NMR (50 MHz, CDCl3+DMSO-d6.): δ 168.5 
(CO), 156.6 (ArC), 147.3 (ArC), 133.2 (ArC), 130.4 
(ArC), 127.9 (2ArCH), 126.9 (2ArCH), 125.4 
(ArCH), 124.5 (ArCH), 121.9 (ArCH), 119.8 (ArCH), 
119.1 (ArCH), 40.8 (CH2); MS (ESI+): m/z 269 
(M+H)+. Anal. Calcd for C15H12N2OS: C, 67.14;  




It was obtained by using 2-amino-5-nitrothiazole 
(0.25 g, 1.72 mmol), phenylacetic acid (0.25 g,  
1.83 mmol), DMAP (0.22 g, 1.80 mmol), HOBt  
Table II — In vitro antitubercular activities of compounds 1-11 
against M. tuberculosis virulent strain M. tuberculosis H37Rv. 
S. No. Compd MIC (μg/mL) 
M. tuberculosis H37Rv 
1 1 > 12.5 
2 2 > 12.5 
3 3 > 12.5 
4 4 > 12.5 
5 5 12.5 
6 6 > 12.5 
7 7 > 12.5 
8 8 12.5 
9 9 > 12.5 
10 10 > 12.5 
11 11 12.5 
12 Isoniazid (INH) 0.02 
13 Rifampicin 0.20 
14 Ethambutol 2.0 
MIC = Minimum inhibitory concentration, the lowest
concentration of the compound which inhibits the growth of
mycobacterium >90%. Isoniazid, rifampicin, and ethambutol used
as the control, against M. tuberculosis H37 Rv. 
 
Table III — Bio-evaluation of compounds against 
 Mycobacterial PknG 
S. No. Compd Inhibition at 100µM (%) 
1 1 12.8 
2 2 15.6 
3 3 14.0 
4 4 12.9 
5 5 10.7 
6 6 10.2 
7 7 10.2 
8 8 10.7 
9 9 10.9 
10 10 9.1 
11 11 NA 
12 AX20017 41% 
NA = not active 




(0.24 g, 1.78 mmol), DIC (0.3 mL, 1.91 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 3 as a white solid powder (0.38 g. Yield 
84%). Rf 0.5 (40% hexane:ethylacetate). m.p. 
195-196°C. IR (KBr): 3429, 3278, 3150, 2925, 2365, 
1705, 1654, 1561, 1345, 1145, 770, 722 cm−1; 
1H NMR (200 MHz, CDCl3+DMSO-d6): δ 8.31  
(s, 1H, ArH), 7.35-7.27 (m, 5H, ArH), 3.85 (s, 2H, 
CH2); 13C NMR (50 MHz, CDCl3+ DMSO-d6.): δ 
169.7 (CO), 164.2 (ArC), 141.6 (ArC), 140.3 (ArCH), 
132.7 (ArC), 128.3 (2ArCH), 127.5 (2ArCH), 126.2 
(ArCH), 41.1 (CH2); MS (ESI+): m/z 264 (M+H)+. 
Anal. Calcd for C11H9N3O3S: C, 50.18; H, 3.45; N, 
15.96. Found: C, 50.15; H, 3.48; N, 15.94%. 
 
N-(6-Ethoxy-1,3-benzothiazol-2-yl)-2-phenylacetamide, 4 
It was obtained by using 2-amino-6-
ethoxybenzothiazole (0.25 g, 1.29 mmol), 
phenylacetic acid (0.19 g, 1.39 mmol), DMAP  
(0.17 g, 1.39 mmol), HOBt (0.18 g, 1.33 mmol), DIC  
(0.3 mL, 1.91 mmol) and dichloromethane (50 mL) as 
described above to give compound 4 as a white solid 
powder (0.35 g. Yield 88%). Rf 0.5 (40% 
hexane:ethylacetate). m.p.130-132°C. IR (KBr): 3421, 
3238, 3182, 2935, 2355, 1690, 1602, 1260, 1057, 725 
cm−1; 1H NMR (200 MHz, CDCl3+CCl4): δ 7.40 (dd, 
J1 = 0.9 Hz, J2 = 5.8 Hz, 1H, ArH), 7.35-7.28 (m, 6H, 
ArH), 7.05 (dd, J1 = 1.7 Hz, J2 = 5.8 Hz, 1H, ArH) 
4.12 (q, J = 4.6 Hz, 2H, OCH2), 3.85 (s, 2H, CH2), 
1.46 (t, J = 4.6 Hz, 3H, CH3); 13C NMR (50 MHz, 
CDCl3+ DMSO-d6): δ 169.3 (CO), 155.6 (ArC), 155.2 
(ArC), 142.5(ArC), 134.4 (ArC), 132.7 (ArC) , 128.9 
(2ArCH), 127.9 (2ArCH), 126.5 (ArCH), 120.7 
(ArCH), 114.8 (ArCH), 104.5 (ArCH), 63.4 (OCH2), 
41.9 (CH2), 14.5 (CH3); MS (ESI+): m/z 313 (M+H)+. 
Anal. Calcd for C17H16N2O2S: C, 65.36; H, 5.16; N, 
8.97. Found: C, 65.33; H, 5.19; N, 8.94%. 
 
N-(6-Fluoro-1,3-benzothiazol-2-yl)-2-phenylacetamide, 5 
It was obtained by using 2-amino-6-
fluorobenzothiazole (0.25 g, 1.49 mmol), phenylacetic 
acid (0.21 g, 1.54 mmol), DMAP (0.19 g, 1.55 mmol), 
HOBt (0.21 g, 1.55 mmol), DIC (0.3 mL, 1.91 mmol) 
and dichloromethane (50 mL) as described above to give 
compound 5 as a white solid powder (0.36 g. Yield 
84%). Rf 0.5 (40% hexane:ethylacetate). m.p.179-180°C. 
IR (KBr): 3430, 2858, 1615, 1551, 1215, 765 cm−1; 
1H NMR (200 MHz, CDCl3+DMSO-d6): δ 7.50-7.46 
(m, 1H, ArH), 7.38-7.34 (m, 1H, ArH), 7.32-7.25 (m, 
5H, ArH), 7.14-7.08 (m, 1H, ArH), 3.83 (s, 2H, CH2); 
13C NMR (50 MHz, CDCl3+ DMSO-d6.): δ 169.7 (CO), 
157.6 (ArC), 145.0 (ArC), 134.3 (ArC), 132.7 (ArC), 
132.5 (ArC), 129.0 (2ArCH), 128.1 (2ArCH), 126.6 
(ArCH), 121.3(ArCH), 121.1(ArCH), 113.9 (ArCH), 
107.7 (ArCH), 41.8 (CH2); MS (ESI+): m/z 287 (M+H)+. 
Anal. Calcd for C15H11FN2OS: C, 62.92; H, 3.87; N, 
9.78. Found: C, 62.89; H, 3.90; N, 9.74%. 
 
N-(1,3-Thiazol-2-yl)pyridine-3-carboxamide, 6 
It was obtained by using 2-aminothiazole (0.25 g, 
2.50 mmol), nicotinic acid (0.32 g, 2.60 mmol), 
DMAP (0.32 g, 2.62 mmol), HOBt (0.35 g, 2.59 
mmol), DIC (0.4 mL, 2.55 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 6 as a white solid powder (0.40 g. Yield 
78%). Rf 0.5 (2:98 MeOH:CHCl3). m.p.> 200°C. IR 
(KBr): 3025, 2364, 1650, 1561, 1215, 765 cm−1; 
1H NMR (300 MHz, CDCl3+DMSO-d6): δ 9.24  
(s, 1H, ArH), 8.67 (d, J = 4.7 Hz, 1H, ArH), 8.35  
(d, J = 8.0 Hz, 1H, ArH), 7.49-7.34 (m, 2H, ArH), 
6.91 (d, J = 3.5 Hz, 1H, ArH); 13C NMR (50 MHz, 
CDCl3+DMSO-d6.): δ 163.5 (CO), 158.6 (ArC), 152.4 
(ArCH), 149.1 (ArCH), 136.9 (ArCH),  
135.5 (ArCH), 127.9 (ArC), 123.1 (ArCH),  
113.4 (ArCH); MS (ESI+): m/z 206 (M+H)+. Anal. 
Calcd for C9H7N3OS: C, 52.67; H, 3.44; N, 20.47. 
Found: C, 52.63; H, 3.48; N, 20.43%. 
 
N-(1,3-Benzothiazol-2-yl)pyridine-3-carboxamide, 7 
It was obtained by using 2-aminobenzothiazole 
(0.25 g, 1.66 mmol), nicotinic acid (0.21 g,  
1.71 mmol), DMAP (0.21 g, 1.71 mmol), HOBt  
(0.24 g, 1.78 mmol), DIC (0.3 mL, 1.91 mmol) and 
dichloromethane (50 mL) as described above to 
 give compound 7 as a white solid powder (0.35 g. 
Yield 83%). Rf 0.5 (50:50 Ethylacetate:Hexane). 
m.p.> 200°C. IR (KBr): IR (KBr): 3415, 3364, 3321, 
2666, 2360, 1675, 1600, 1280, 741, 640 cm−1; 
1H NMR (200 MHz, CDCl3+DMSO-d6): δ 9.34  
(d, J = 0.9 Hz, 1H, ArH), 8.77 (d, J = 2.2 Hz, 1H, 
ArH), 8.52-8.49 (m, 1H, ArH), 7.87 (d, J = 5.0 Hz, 
1H, ArH), 7.77 (d, J = 5.7 Hz, 1H, ArH), 7.50-7.39 
(m, 2H, ArH), 7.33-7.28 (m, 1H, ArH); 13C NMR  
(50 MHz, CDCl3+ DMSO-d6.): δ 163.3 (CO), 157.4 
(ArC), 151.2 (ArCH), 147.7 (ArCH), 146.1 (ArC), 
134.2 (ArCH), 129.6 (ArC), 126.3 (ArC), 124.4 
(ArCH), 121.9 (ArCH), 121.7 (ArCH), 119.9 (ArCH), 
118.4 (ArCH); MS (ESI+): 256 (M+H)+. Anal. Calcd 
for C13H9N3OS: C, 61.16; H, 3.55; N, 16.46. Found: 
C, 61.12; H, 3.58; N, 16.42%. 




N-{2-Oxo-2-[(1,3-thiazol-2-yl)amino] ethyl}be nzamide, 8 
It was obtained by using 2-aminothiazole (0.25 g, 
2.50 mmol), hippuric acid (0.46 g, 2.56 mmol), 
DMAP (0.32 g, 2.62 mmol), HOBt (0.35 g, 2.59 
mmol), DIC (0.4 mL, 2.55 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 8 as a white solid powder (0.52 g. Yield 
80%). Rf 0.5 (40% hexane:ethylacetate). m.p.> 200°C. 
IR (KBr): 3560, 3345, 2925, 2365, 1780, 1650, 1530, 
1290, 1167, 955, 705 cm−1; 1H NMR (200 MHz, 
CDCl3+DMSO-d6): δ 8.65 (bs, 1H, NH), 7.92 (d,  
J = 4.6 Hz, 2H, ArH), 7.50-7.38 (m, 4H, ArH),  
6.98-6.97 (m, 1H, ArH), 4.23 (d, J = 3.8 Hz, 2H, 
CH2); 13C NMR (50 MHz, CDCl3+ DMSO-d6.): δ 
173.0 (CO), 172.1 (CO), 163.1 (ArC), 142.5 (ArC), 
138.9 (ArCH), 136.4 (ArCH), 133.2 (2ArCH), 132.5 
(2ArCH), 118.0 (ArCH), 47.8 (ArCH); MS (ESI+): 
262 (M+H)+. Anal. Calcd for C12H11N3O2S: C, 55.16; 




It was obtained by using 2-aminothiazole (0.25 g, 
2.50 mmol), cinnamic acid (0.39 g, 2.63 mmol), 
DMAP (0.32 g, 2.62 mmol), HOBt (0.35 g, 2.59 
mmol), DIC (0.4 mL, 2.55 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 9 as a white solid powder (0.48 g. Yield 
84%). Rf 0.5 (40% hexane:ethylacetate). m.p.> 200°C. 
IR (KBr): 3531, 2860, 1625, 1541, 1325, 1215, 760, 
670 cm−1; 1H NMR (200 MHz, CDCl3+DMSO-d6):  
δ 7.76 (d, J = 10.0 Hz, 1H, CH), 7.59-7.57 (m, 2H, 
ArH), 7.47-7.40 (m, 4H, ArH), 7.04 (d, J = 2.0 Hz, 
1H, ArH), 6.94 (d, J = 10.0 Hz, 1H, CH); MS (ESI+): 
231 (M+H)+. Anal. Calcd for C12H10N2OS: C, 62.59; 





It was obtained by using 2-aminobenzothiazole 
(0.25 g, 1.66 mmol), cinnamic acid (0.26 g, 1.75 
mmol), DMAP (0.21 g, 1.71 mmol), HOBt (0.24 g, 
1.78 mmol), DIC (0.3 mL, 1.91 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 10 as a white solid powder (0.40 g. Yield 
85%). Rf 0.5 (50% hexane:ethylacetate). m.p.> 
200°C. IR (KBr): 3426, 3171, 2950, 2365, 1687, 
1595, 1550, 1155, 745 cm−1; 1H NMR (200 MHz, 
CDCl3+DMSO-d6): δ 7.73 (d, J = 10.0 Hz, 1H, CH), 
7.70-7.57 (m, 1H, ArH), 7.47-7.43 (m, 2H, ArH), 
7.32-7.24 (m, 4H, ArH), 7.17-6.73 (m, 2H, ArH), 
6.78 (d, J = 10.0 Hz, 1H, CH); MS (ESI): 281 
(M+H)+. Anal. Calcd for C16H12N2OS: C, 68.55; H, 




It was obtained by using 2-amino-5-nitrothiazole 
(0.25 g, 1.72 mmol), cinnamic acid (0.27 g, 1.82 
mmol), DMAP (0.22 g, 1.80 mmol), HOBt (0.24 g, 
1.78 mmol), DIC (0.3 mL, 1.91 mmol) and 
dichloromethane (50 mL) as described above to give 
compound 11 as a white solid powder (0.38 g. Yield 
81%). Rf 0.5 (50% hexane:ethylacetate). m.p.> 200°C. 
IR (KBr): 3447, 3145, 2927, 2705, 1685, 1625, 1555, 
1337, 1155, 760, 480 cm−1; 1H NMR (200 MHz, 
CDCl3+DMSO-d6): δ 8.35 (d, J = 1.1 Hz, 1H, ArH), 
7.87 (d, J = 10.2 Hz, 1H, CH), 7.60-7.42 (m, 5H, 
ArH), 6.90 (d, J = 10.5 Hz, 1H, CH); MS (ESI+): 276 
(M+H)+. Anal. Calcd for C12H9N3O3S: C, 52.36; H, 




Determination of antitubercular activity against M. 
tuberculosis H37Rv strain (Agar microdilution method)30-32 
Determination of MIC and drug susceptibility of 
the test compounds/drugs against M. tuberculosis 
H37Rv were determined by agar microdilution 
methodology. In this method, two-fold dilutions of 
every test compound were added into 7H10 agar and 
M. tuberculosis H37Rv was used as the test organism. 
The MIC of each tested compound was determined by 
incorporating lower concentrations of the tested 
compound in the middle brook 7H10 agar medium 
supplemented with OADC. A culture of M. 
tuberculosis H37Rv, which was growing on L-J 
medium was harvested in 0.85% saline with 0.05% 
Tween-80. A suspension of 1 µg/mL concentration of 
extracts/compounds was prepared in dimethyl 
sulphoxide. This suspension was added to (in tubes) 
7H10 middle Brook’s medium (containing 1.7 mL 
medium and 0.2 mL OADC supplement) at different 
concentrations of the test compounds keeping the 
volume constant (0.1 mL). The medium was allowed 
to cool gradually keeping the tubes in slanting 
position. After this, these tubes were incubated at 
37°C for 24 h followed by streaking of M. 
tuberculosis H37Rv (5 × 104 bacilli per test tube). 
These tubes were then allowed to incubate at 37°C. 




The growth of bacilli was observed after 30 days of 
incubation. Tubes having the test compounds were 
compared with control tubes where medium alone 
was incubated with H37Rv. The concentration at 
which complete inhibition of colonies took place was 
taken as an active concentration of test compounds. 
 
Purification of Mycobacterium tuberculosis PKnG33 
The synthesized compounds were tested or 
screened against the mycobacterial serine-threonine 
protein kinase G (PknG). The recombinantly purified 
enzyme was used for the present study. In short, the 
Mycobacterium tuberculosis (MTB) genomic DNA 
was used as a template for the amplification of the 
pknG gene by PCR. The gene was cloned in pTriEx4 
vector using the primers containing the desired 
restriction enzyme sites. For expression in pknG,  
E coli with HindIII flanking sites was subcloned in 
pTriEx4 vector E. coli BL21 (DE3). Cells were 
transformed with pTriEX4-pknG and transformants 
were allowed to grow in LB medium containing 
ampicillin (100 μg/mL) at temperature 37°C, till OD 
at 600 nm reached 0.6. IPTG was then added to a final 
concentration of 0.8 mM and cultures were further 
expedited for an additional 4 h at 37°C with shaking. 
Cells were harvested by centrifugation at 5000 × g for 
15 min and resuspended in binding buffer [sodium 
phosphate 20.0 mM (pH 7.4), NaCl 50.0 mM, 
imidazole 5.0 mM, PMSF 1.0 mM] and sonicated on 
ice for 2 min. After sonication, TritonX-100 was 
added in cell lysate at an eventual concentration of 
1% before centrifugation at 30000 × g for 30 min at 
temperature 4°C. The supernatant was loaded onto 
Ni2+-NTA column, washed with 60 mM imidazole 
and 6-His-PknG was eluted with 200 mM imidazole. 
Affinity purified 6-His-PknG was further purified by 
size exclusion chromatography using a sephacryl  
200 column and AKTA Prime protein purification 
system (GE healthcare). 
 
Screening of compounds against Kinase activity 
All the synthesized compounds were dissolved 
completely in DMSO. Primary efficacy was 
determined by using 100 μM concentration of each 
compound, which was screened using purified PknG 
as an enzyme and myelin basic protein as a substrate. 
The activity and the inhibition were determined with 
the help of luciferase activity mediated by ATP, by 
ADP–Glo (Promega, USA). Briefly, ADP-Glo™ 
Kinase Assay is a luminescent kinase assay, which 
measures ADP formed from a kinase reaction. ADP is 
converted into ATP, which is then converted into light 
by Ultra-Glo™ Luciferase. 
 
Conclusions 
In the present study, we have synthesized and 
characterized a series of thiazole unit based 
compounds having an amide group at its 2-position by 
using different aromatic acids. A few of these 
compounds have good PknG inhibitory activity. Nearly 
all the compounds showed very moderate antitubercular 
activity against the H37Rv virulent strain of  
M. tuberculosis. These findings led us to the 
identification of a new prototype of compounds for 
further optimization and development to get novel 
compounds having promising PknG inhibitory activity. 
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